Skip to main content

Did you miss "Mad Money" on CNBC? If so, here are some of Jim Cramer's top takeaways.

Image placeholder title

For an "Executive Decision" segment, Cramer sat down with Mike Mussallem, chairman and CEO of Edwards Lifesciences (EW) - Get Edwards Lifesciences Corporation Report , the medical device maker with shares that are up 13% over the past year.

Mussallem explained that Edwards was founded on revolutionary heart valve technology and over the past 20 years, that technology has only been getting better and better. What was once an open heart procedure requiring more than a week in the hospital and weeks thereafter of tough recovery has now been completely transformed.

Mussallem continued by explaining that Edwards' newest heart valve can be squeezed into a catheter and implanted intravenously in about an hour. Patients don't even require general anesthesia and can be awake for the procedure. These new valves are better for everyone -- with better technology, better outcomes and better economics.

Cramer said shares of Edwards Lifesciences are not done going up, as the company's products are revolutionary.

Scroll to Continue

TheStreet Recommends

On Real Money, Cramer says that despite the incredible run in the market and the mess in Washington, there could yet be some real firepower that could come off the sidelines and into this market. Get his insights with a free trial subscription to Real Money.

Cramer and the AAP team are telling their investment club members that the big news driving their portfolio today is centered around oil. Get in on the conversation with a free trial subscription to Action Alerts PLUS.

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

To read a full recap of this episode of "Mad Money," click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.